Aktienanalyse zu Verastem Inc (VSTM)VSTMVerastem Inc

Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Verastem Inc (VSTM) appears to be a good buy right now, with a current price of $8.38 and a strong RSI of 64.7 indicating bullish momentum. The stock has seen a 5-day change of +8.83% and a year-to-date change of +15.91%, reflecting positive investor sentiment. However, the main risk is its negative earnings per share (EPS) of -0.35 reported in the last quarter, which indicates ongoing losses.

5 analysts cover VSTM: 4 rate it Buy, 1 Hold and 0 Sell. The average price target is 15.60.